The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 50 条
  • [41] ASSESSING THE BUDGET IMPACT OF USING SCANBAG® IN CT IN SIX EUROPEAN COUNTRIES
    Nivelle, E.
    Mathou, F.
    Lamotte, M.
    VALUE IN HEALTH, 2012, 15 (04) : A64 - A64
  • [42] Socioeconomic Status and the Prevalence of Skin and Atopic Diseases in Five European Countries
    Ofenloch, Robert F.
    Schuttelaar, Marie Louise A.
    Svensson, Ake
    Bruze, Magnus
    Naldi, Luigi
    Cazzaniga, Simone
    Elsner, Peter
    Goncalo, Margarida
    Diepgen, Thomas L.
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (03) : 309 - 314
  • [43] The budget impact of implementing atrial fibrillation-screening in European countries
    Eklund, Michaela
    Bernfort, Lars
    Appelberg, Kajsa
    Engler, Daniel
    Schnabel, Renate B.
    Martinez, Carlos
    Wallenhorst, Christopher
    Boriani, Giuseppe
    Buckley, Claire M.
    Diederichsen, Soren Zoga
    Svendsen, Jesper Hastrup
    Montaner, Joan
    Potpara, Tatjana
    Levin, Lars-Ake
    Lyth, Johan
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26 : iv19 - iv32
  • [44] COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
    Despiegel, N.
    Cirillo, L.
    Gaikwad, I
    VALUE IN HEALTH, 2019, 22 : S458 - S458
  • [45] A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
    Brodszky, Valentin
    Rencz, Fanni
    Pentek, Marta
    Baji, Petra
    Lakatos, Peter L.
    Gulacsi, Laszlo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (01) : 119 - 125
  • [46] The impact of infliximab treatment on the quality of life in patients with rheumatologic diseases
    Han, C
    Zhao, N
    Baker, D
    Bala, M
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 394 - 394
  • [47] Selenium status in patients with autoimmune and non-autoimmune thyroid diseases from four European countries
    Krassas, Gerasimos E.
    Pontikides, Nikolaos
    Tziomalos, Kostas
    Tzotzas, Themistoklis
    Zosin, Ioana
    Vlad, Mihaela
    Luger, Anton
    Gessl, Alois
    Marculescu, Rodrig
    Toscano, Vincenzo
    Morgante, Sara
    Papini, Enrico
    Pirags, Valdis
    Konrade, Ilze
    Hybsier, Sandra
    Hofmann, Peter J.
    Schomburg, Lutz
    Kohrle, Josef
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (06) : 685 - 692
  • [48] Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries
    Andrea Marcellusi
    Chiara Bini
    Massimo Andreoni
    Loredana Sarmati
    Jaime Espin
    Juan P. Horcajada
    Thomas Czypionka
    Davide Andretta
    Paolo Sciattella
    Giampiero Favato
    Francesco S. Mennini
    Clinical Drug Investigation, 2020, 40 : 305 - 318
  • [49] Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries
    Marcellusi, Andrea
    Bini, Chiara
    Andreoni, Massimo
    Sarmati, Loredana
    Espin, Jaime
    Horcajada, Juan P.
    Czypionka, Thomas
    Andretta, Davide
    Sciattella, Paolo
    Favato, Giampiero
    Mennini, Francesco S.
    CLINICAL DRUG INVESTIGATION, 2020, 40 (04) : 305 - 318
  • [50] Heroin assisted treatment of opiate dependence in five European countries
    Haasen, C
    EUROPEAN PSYCHIATRY, 2005, 20 : S18 - S18
12345